MediGene AG (ETR:MDG1) has been assigned a €12.00 ($14.12) price target by Oddo Securities in a report released on Tuesday. The brokerage presently has a “buy” rating on the stock.

Several other research firms have also recently weighed in on MDG1. Baader Bank set a €19.00 ($22.35) price objective on MediGene AG and gave the stock a “buy” rating in a report on Thursday, August 3rd. Independent Research GmbH set a €12.00 ($14.12) price objective on MediGene AG and gave the stock a “neutral” rating in a report on Monday, May 29th.

MediGene AG (MDG1) traded down 2.051% during midday trading on Tuesday, hitting €9.981. The stock had a trading volume of 3,333 shares. The firm’s 50-day moving average price is €10.89 and its 200 day moving average price is €11.70. The company’s market cap is €201.10 million. MediGene AG has a 12 month low of €6.63 and a 12 month high of €15.19.

ILLEGAL ACTIVITY WARNING: “Oddo Securities Analysts Give MediGene AG (ETR:MDG1) a €12.00 Price Target” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at

About MediGene AG

Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors.

Receive News & Ratings for MediGene AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediGene AG and related companies with's FREE daily email newsletter.